{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:29:42Z","timestamp":1792751382960,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tzu Chi Med J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/tcmj.tcmj_220_18","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T04:53:29Z","timestamp":1552539209000},"page":"58","source":"Crossref","is-referenced-by-count":3,"title":["Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study"],"prefix":"10.4103","volume":"32","author":[{"given":"Jamshid","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EbrahimMoghimi","family":"Sarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinaSefidfard","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1016-3190.254208-1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/1016-3190.254208-2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2105\/AJPH.85.8_Pt_1.1157","article-title":"The rise of the modern addict","author":"Jonnes","year":"1995","journal-title":"Am J Public Health"},{"key":"key-10.4103\/1016-3190.254208-3","unstructured":"Sadock B, Sadock V, Ruiz P, editors. Kaplan and Shaddock's synopsis of psychiatry. Philadelphia (USA): Lippincott Williams and Wilkins; 2015."},{"key":"key-10.4103\/1016-3190.254208-4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"key-10.4103\/1016-3190.254208-5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"key-10.4103\/1016-3190.254208-6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/02791072.1994.10472259","article-title":"Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine","author":"Ling","year":"1994","journal-title":"J Psychoactive Drugs"},{"key":"key-10.4103\/1016-3190.254208-7","first-page":"1025","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","author":"Strain","year":"1994","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/1016-3190.254208-8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","author":"Johnson","year":"1992","journal-title":"JAMA"},{"key":"key-10.4103\/1016-3190.254208-9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"key-10.4103\/1016-3190.254208-10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1989.66","article-title":"Sublingual versus subcutaneous buprenorphine in opiate abusers","author":"Jasinski","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/1016-3190.254208-11","first-page":"517","article-title":"The effects of morphine- and nalorphinelike drugs in the non-dependent and morphine dependent chronic spinal dog","author":"Martin","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/1016-3190.254208-12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/1016-3190.254208-13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-2999(88)90149-5","article-title":"Kappa antagonist properties of buprenorphine in the shock titration procedure","author":"Negus","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/1016-3190.254208-14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0014-2999(88)90543-2","article-title":"Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice","author":"Leander","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/1016-3190.254208-15","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/00005344-198300051-00002","article-title":"Intrinsic activity: Partial agonists and partial antagonists","author":"Ari\u00ebns","year":"1983","journal-title":"J Cardiovasc Pharmacol"},{"key":"key-10.4103\/1016-3190.254208-16","first-page":"966","article-title":"Treatment of heroin abuse","author":"Ahmadi","year":"2015","journal-title":"Sch Acad J Biosci"},{"key":"key-10.4103\/1016-3190.254208-17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13063-017-2007-3","article-title":"Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: A randomized clinical trial","author":"Ahmadi","year":"2017","journal-title":"Trials"},{"key":"key-10.4103\/1016-3190.254208-18","first-page":"e57510","article-title":"Fast effect of buprenorphine on opioid-dependent patients with suicidal ideation: A novel approach","author":"Ahmadi","year":"2018","journal-title":"Int J High Risk Behav Addict"},{"key":"key-10.4103\/1016-3190.254208-19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"key-10.4103\/1016-3190.254208-20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6","article-title":"Scale for suicide ideation: Psychometric properties of a self-report version","author":"Beck","year":"1988","journal-title":"J Clin Psychol"},{"key":"key-10.4103\/1016-3190.254208-21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pnpbp.2005.10.007","article-title":"Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study","author":"Gerra","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/1016-3190.254208-22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-859X-10-17","article-title":"Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?","author":"Maremmani","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"key-10.4103\/1016-3190.254208-23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"key-10.4103\/1016-3190.254208-24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u03bc-opioid receptor activation","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"key-10.4103\/1016-3190.254208-25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/0253-7176.211765","article-title":"Anxiety treatment of opioid dependent patients with buprenorphine: A randomized, double-blind, clinical trial","author":"Ahmadi","year":"2017","journal-title":"Indian J Psychol Med","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7176","issn-type":"print"},{"key":"key-10.4103\/1016-3190.254208-26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/10826084.2017.1400063","article-title":"Ultrarapid influence of buprenorphine on major depression in opioid-dependent patients: A double blind, randomized clinical trial","author":"Ahmadi","year":"2018","journal-title":"Subst Use Misuse"},{"key":"key-10.4103\/1016-3190.254208-27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2362.2003.01218.x","article-title":"Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study","author":"Ahmadi","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"key-10.4103\/1016-3190.254208-28","first-page":"23","article-title":"Treatment of intravenous buprenorphine dependence: A randomized open clinical trial","author":"Ahmadi","year":"2003","journal-title":"German J Psychiatry"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:44:59Z","timestamp":1786715099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_220_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["254208"],"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_220_18","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}